Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
US-9221759-B2 · Dec 29, 2015 · US
2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9376392B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9376392-B2 |
| Application number | US-201314370464-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 3, 2013 |
| Priority date | Jan 4, 2012 |
| Publication date | Jun 28, 2016 |
| Grant date | Jun 28, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound or a pharmaceutically acceptable salt thereof, selected from the group consisting of: 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of: 3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of: 4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of: 5. A pharmaceutical composition comprising a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 6. A pharmaceutical composition comprising a compound as described in claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
not condensed and containing further heterocyclic rings · CPC title
2-Quinolinones, e.g. carbostyril · CPC title
- C07D215/227Primary
only one oxygen atom which is attached in position 2 · CPC title
containing further heterocyclic rings · CPC title
Peri-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9376392B2 cover?
- The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delayi…
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D215/227. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).